The first-line treatment of advanced NSCLC without actionable mutations has undergone a dramatic change over the last 5 years, with the standard of care changing from chemotherapy to immune checkpoint inhibitor (ICI) monotherapy for select patients, to a variety of ICI-based combination regimens in addition to monotherapy.
This activity has been designed to address the educational needs of community and academic physicians specializing in hematology and hematology/oncology. It will also benefit other clinicians who manage patients with Castleman disease (CD).
Oncology clinicians would benefit from this educational activity through updates on a multidisciplinary approach to optimally managing patients with pancreatic cancer, with a focus on the efficacy and safety data of current guideline-recommended regimens as well as information on emerging therapies.
